Skip to main content
. 2021 Nov 23;3(1):100256. doi: 10.1016/j.jtocrr.2021.100256

Table 3.

Treatment-Related Serious Adverse Events Observed

Toxicity Observed Timing of Event Dose Level Comments
Left ventricular ejection fraction decrease C2D1 1 Asymptomatic, LV thrombus identified
Atrial fibrillation C2D8 1 Clinical heart failure
Pulmonary embolus C1D12 1 with hemoptysis, ICU stay
Myocardial infarction C1D19 2 ST elevation myocardial infarction
Gastrointestinal bleed C4D8 2 Grade 5 (required before dose reduction)

ICU, intensive care unit; LV, left ventricle.